pegylated interferon lambda + daclatasvir + ribavirin

**Pegylated interferon lambda + daclatasvir + ribavirin** is a triple combination therapy of three antiviral agents investigated primarily for the treatment of chronic hepatitis C virus (HCV) infection, including in populations coinfected with HCV and human immunodeficiency virus (HIV)[1][3][7][9]. Pegylated interferon lambda is a type III interferon engineered to have a longer half-life, daclatasvir is a potent NS5A inhibitor that blocks HCV replication, and ribavirin is a nucleoside analog with broad-spectrum antiviral activity. The combination is designed to improve sustained virologic response rates (SVR12) and tolerability over regimens using alpha interferons. In clinical studies, this regimen demonstrated high efficacy, especially for HCV genotypes 1b and 2, as well as a relatively favorable safety profile compared to interferon alfa-based regimens[1][3][7][9].

Brand names

DAKLINZA (for daclatasvir)

Other names

peginterferon lambda-1a + daclatasvir + ribavirinLambda/RBV/DCV